Valuation: UCB

Capitalization 45.42B 52.82B 41.58B 39.28B 72.59B 5,102B 73.76B 493B 193B 2,408B 198B 194B 8,388B P/E ratio 2026 *
25.9x
P/E ratio 2027 * 19.9x
Enterprise value 43.93B 51.09B 40.22B 38B 70.22B 4,935B 71.34B 477B 187B 2,329B 192B 188B 8,114B EV / Sales 2026 *
5.19x
EV / Sales 2027 * 4.41x
Free-Float
61.59%
Yield 2026 *
0.61%
Yield 2027 * 0.63%
1 day+0.38%
1 week-0.33%
Current month+3.59%
1 month-3.08%
3 months-11.36%
6 months+2.79%
Current year+0.38%
1 week 228.7
Extreme 228.7
240.9
1 month 223
Extreme 223
248.8
Current year 223
Extreme 223
289.5
1 year 152.95
Extreme 152.95
289.5
3 years 65.4
Extreme 65.4
289.5
5 years 65.4
Extreme 65.4
289.5
10 years 54.84
Extreme 54.84
289.5
Manager TitleAgeSince
Chief Executive Officer 67 01/01/2015
Director of Finance/CFO 59 01/07/2020
Chief Tech/Sci/R&D Officer 59 01/05/2024
Director TitleAgeSince
Director/Board Member 67 28/04/2016
Director/Board Member 75 01/01/2014
Director/Board Member 67 01/01/2015
Change 5d. change 1-year change 3-years change Capi.($)
+0.42%-0.33%+46.35%+174.34% 52.82B
+3.09%-9.74%+5.69%-14.40% 66.11B
-0.67%+33.70%+33.70%+33.70% 41.34B
+1.60%+2.87%-59.20%-67.44% 34.22B
-1.45%-8.18%+43.85%-39.12% 27.73B
+1.55%-1.76%+48.67%+52.71% 19.39B
+5.25%-4.56%+71.92%-61.88% 19.09B
+3.97%-4.79%+47.67%+112.48% 17.59B
+0.27%-0.82%+41.10%+83.17% 16.17B
-1.91%+1.55%+13.23%+661.65% 12.85B
Average +0.79%-4.84%+29.30%+93.52% 30.73B
Weighted average by Cap. +1.01%-5.15%+24.07%+58.33%

Financials

2026 *2027 *
Net sales 8.46B 9.84B 7.74B 7.31B 13.52B 950B 13.73B 91.78B 35.92B 448B 36.91B 36.13B 1,562B 9.53B 11.08B 8.73B 8.24B 15.23B 1,071B 15.48B 103B 40.48B 505B 41.6B 40.72B 1,760B
Net income 1.76B 2.05B 1.61B 1.52B 2.82B 198B 2.86B 19.13B 7.49B 93.47B 7.69B 7.53B 326B 2.26B 2.63B 2.07B 1.96B 3.62B 254B 3.68B 24.58B 9.62B 120B 9.88B 9.67B 418B
Net Debt -1.49B -1.73B -1.36B -1.29B -2.38B -167B -2.41B -16.14B -6.31B -78.84B -6.49B -6.35B -275B -3.43B -3.98B -3.14B -2.96B -5.47B -385B -5.56B -37.17B -14.55B -182B -14.95B -14.63B -633B
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,765
Date Price Change Volume
21/05/26 239.60 +0.42% 8,604
20/05/26 238.60 +1.58% 208,579
19/05/26 234.90 +2.17% 271,822
18/05/26 229.90 -3.00% 235,494
15/05/26 237.00 -1.37% 151,927
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
238.60EUR
Average target price
288.21EUR
Spread / Average Target
+20.79%

Quarterly revenue - Rate of surprise